Overview

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

Status:
NOT_YET_RECRUITING

Trial end date:
2031-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.

Phase:

PHASE3

Details

Lead Sponsor:

Syndax Pharmaceuticals

Treatments:

revumenib